Elutia agrees to sell SimpliDerm business to Cellution Biologics for up to $11 million

Reuters2026/07/20 20:08

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elutia agreed to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million.
Consideration includes $8 million cash at closing, with up to $3 million tied to technology transfer and commercial milestones over 18 months.
Closing is expected in the second half of 2026, subject to customary closing conditions.
Divestiture is set to sharpen focus on NXT-41x, targeting a 2027 commercial launch in U.S. plastic and reconstructive surgery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-085061), on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elutia agrees to sell SimpliDerm business to Cellution Biologics for up to $11 million

You may also like

Crypto prices